StockData
Kyverna Therapeutics, Inc. logo

Kyverna Therapeutics, Inc. (KYTX) stock

KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$4.48−0.22 (-4.68%)

Close on Nov 18, 2026Market cap $277.06MP/E –Yield –

Kyverna Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Kyverna Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$163.10M. For fiscal 2025 it was -$169.83M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$169.83M–
FY2024Dec 31, 2024-$142.60M–
FY2023Dec 31, 2023-$62.41M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$42.90M–
Q2 FY2026Jun 30, 2026-$39.56M–
Q1 FY2026Mar 31, 2026-$41.37M–
Q4 FY2025Dec 31, 2025-$39.28M–
Q3 FY2025Sep 30, 2025-$38.73M–
Q2 FY2025Jun 30, 2025-$44.41M–
Q1 FY2025Mar 31, 2025-$47.41M–
Q4 FY2024Dec 31, 2024-$41.04M–
Q3 FY2024Sep 30, 2024-$38.77M–
Q2 FY2024Jun 30, 2024-$33.44M–
Q1 FY2024Mar 31, 2024-$29.36M–
Q4 FY2023Dec 31, 2023-$21.38M–
Q3 FY2023Sep 30, 2023-$16.28M–
Q2 FY2023Jun 30, 2023-$13.30M–
Q1 FY2023Mar 31, 2023-$11.45M–

More Kyverna Therapeutics figures

See a number that looks wrong?